Investment Rating - The report maintains an "Outperform" rating for the company [6][3]. Core Insights - The company reported a revenue of $2.489 billion in Q4 2025, exceeding guidance and achieving a year-over-year growth of 12.8% [1]. - The gross margin decreased to 19.2% due to increased depreciation, which aligns with guidance [1]. - The company expects revenue growth in 2026 to surpass the average growth of comparable peers [1]. - The company plans to acquire 49% of the minority stake in SMIC North and increase its stake in SMIC South from 38.515% to 41.561% [3]. - The revenue from the industrial and automotive sectors grew significantly, with year-over-year increases of 81.4% and 43.4%, respectively [2]. Financial Performance - Q4 2025 sales revenue reached $2.489 billion, with wafer revenue accounting for 92.4% of total revenue [1]. - The company shipped 2.51 million 8-inch wafers in Q4 2025, a year-over-year increase of 26.3% [1]. - Capital expenditures for Q4 2025 were $2.408 billion, a 45% increase year-over-year [1]. - The company expects capital expenditures in 2026 to remain approximately the same as in 2025, around $8.1 billion [1]. Revenue and Profit Forecast - The company forecasts revenues of $9.327 billion, $11.008 billion, and $12.532 billion for 2025, 2026, and 2027, respectively, with growth rates of 16.2%, 18.0%, and 13.8% [5]. - Net profit estimates for 2025, 2026, and 2027 are $685 million, $876 million, and $1.031 billion, respectively, reflecting growth rates of 39.1%, 27.8%, and 17.7% [5].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 105.00, indicating a potential upside of 17.1% from the current price of HKD 89.65 [1][9]. Core Insights - The company has successfully secured a strategic partnership with Eli Lilly, marking its seventh collaboration and validating its antibody technology platform. This partnership is expected to significantly enhance the company's overseas development of early-stage assets and increase global commercialization certainty [2][7]. - The company anticipates strong commercial growth driven by its comprehensive pipeline in 2026, with projected product revenue growth of approximately 45% year-on-year to RMB 12.505 billion in 2025. Key products are expected to continue providing stable support for revenue growth [7][12]. - The management expects that three key assets, IBI363, IBI343, and IBI324, will enter global Phase III clinical trials, with IBI363 alone projected to contribute over USD 40 billion to the market [7][12]. Financial Forecast Changes - Revenue projections for 2025 have been revised down to RMB 12.505 billion, a decrease of 37.1% from previous estimates, while 2026 revenue is expected to rise to RMB 18.450 billion, an increase of 26.7% [3]. - Gross profit for 2025 is now forecasted at RMB 10.713 billion, down 41.0%, with a gross margin of 85.7%. For 2026, gross profit is expected to increase to RMB 16.064 billion, with a gross margin of 87.1% [3]. - The net profit forecast for 2025 has been significantly reduced to RMB 1.055 billion, a decrease of 87.9%, while 2026 net profit is projected to rise to RMB 3.502 billion, reflecting a 37.8% increase [3]. Stock Performance - The stock has shown a year-to-date increase of 17.57%, with a 52-week high of HKD 107.00 and a low of HKD 35.50, indicating strong market interest [6][11]. Valuation Model - The DCF valuation model estimates the equity value at RMB 161.238 million, translating to a per-share value of HKD 105.00, based on projected free cash flows and a WACC of 9.9% [8][15].

Investment Rating - The report assigns a "Buy" rating for the company, indicating a potential upside in the stock price [6][12]. Core Insights - The company has achieved global sales exceeding 400 million units, with the "THE MONSTERS" series alone accounting for over 100 million units sold [7]. - The company is expected to experience significant revenue growth in 2025, with projected revenues between RMB 35.6 billion and RMB 43.6 billion, representing a year-on-year increase of 173% to 234% [12]. - New product launches in late 2025 and early 2026 have generated positive market responses, with some products showing a premium of approximately 48% [12]. - The company is strengthening its long-term development foundation by expanding its membership base to over 100 million and increasing its global store count to over 700 [12]. - The company is exploring new business avenues, including jewelry, desserts, theme parks, clothing, and film [12]. - Profit forecasts for 2025 to 2027 are optimistic, with expected net profits of RMB 12.26 billion, RMB 17.8 billion, and RMB 24.6 billion, respectively, indicating substantial growth rates [12]. Financial Summary - The company reported a net profit of RMB 476 million in 2022, with projections of RMB 1.08 billion in 2023 and RMB 3.13 billion in 2024, reflecting a significant recovery and growth trajectory [10]. - Earnings per share (EPS) are expected to rise from RMB 0.35 in 2022 to RMB 9.13 in 2025, showcasing a strong growth potential [10]. - The price-to-earnings (P/E) ratio is projected to decrease from 685 in 2022 to 26 in 2025, indicating an attractive valuation as earnings grow [10].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 105.00, indicating a potential upside of 17.1% from the current price of HKD 89.65 [1][9]. Core Insights - The company has successfully secured a strategic collaboration with Eli Lilly, marking its seventh major partnership and validating its antibody technology platform. This collaboration is expected to significantly enhance the company's overseas development of early-stage assets and increase global commercialization certainty [2][7]. - The company anticipates strong commercial growth driven by its oncology and comprehensive pipeline in 2026, with projected product revenue growth of approximately 45% year-on-year to RMB 12.505 billion in 2025. Key products are expected to continue supporting revenue growth [2][7]. - The report highlights the potential market space for key assets, estimating over USD 60 billion, with IBI363 alone contributing more than USD 40 billion. The company is also expected to introduce 8-10 new molecules annually from its innovation pipeline starting in 2026 [2][7]. Financial Forecast Changes - Revenue projections for 2025 have been revised down to RMB 12,505 million, a decrease of 37.1% from previous estimates. However, the 2026 revenue forecast has been increased by 26.7% to RMB 18,450 million, and the 2027 forecast has been raised by 18.6% to RMB 20,830 million [3]. - Gross profit for 2025 is now expected to be RMB 10,713 million, down 41.0% from prior estimates, while the gross profit margin is projected to be 85.7% [3]. - The net profit forecast for 2025 has been significantly reduced to RMB 1,055 million, reflecting an 87.9% decrease from previous estimates, but is expected to rise to RMB 3,502 million in 2026 and RMB 4,341 million in 2027 [3]. Stock Performance - The stock has shown a year-to-date increase of 17.57%, with a 52-week high of HKD 107.00 and a low of HKD 35.50, indicating strong market interest [6][12]. Valuation Model - The discounted cash flow (DCF) valuation model estimates the equity value at RMB 161,238 million, translating to a per-share value of HKD 105.00, based on projected free cash flows and a WACC of 9.9% [8][15].

Investment Rating - The report maintains a "Buy" rating for Li Auto-W (02015) due to its attractive valuation levels [1] Core Insights - Li Auto is currently trading at a valuation level that is lower than 95% of the time since its listing, with net cash accounting for approximately two-thirds of its market value, indicating a very pessimistic market sentiment [1] - The upcoming launch of the new generation L9, priced at 559,800 RMB, is expected to improve market sentiment and visibility regarding other model updates [1] - Despite challenges from rising commodity costs, the company's high-end positioning and profit buffer are anticipated to provide greater resilience compared to most peers [1] - The report suggests that now is an appropriate time to refocus on the stock as the flagship SUV L9 is set to be relaunched in the second quarter, which could drive growth acceleration from a low base in 2025 [1]

MINIMAX-WP(00100):首予"超配"评级,全球化AI先锋,引领下一波价值浪潮 摩根大通 据截止2月10日午盘收盘，MiniMax（00100）股价在港股一度上涨10.7%，其驱动因素之于源于摩根大通近 日研报的首次覆盖。 摩根大通近日首次覆盖港股上市公司MiniMax，给予"超配"（Overweight）评级，并设定700港元的目标 价，较当前股价具备约36%的上行空间。报告指出，MiniMax凭借其稀缺的全球化基因与领先的技术实力，已成 为投资者把握2030年全球人工智能市场——预计规模将达1.4万亿美元——的关键入口。 自今年1月初上市以来，MiniMax股价已飙升逾230%，盘中最高触及599.5港元。 作为中国最具辨识度的独立大模型企业之一，MiniMax正加速推进其全球业务布局。目前，公司超过70%的 营收来自海外市场，API服务随着全球开发者生态的快速拓展而迅猛增长。摩根大通分析师OliviaXu团队指 出："这种高度国际化的收入结构不仅有效实现营收多元化、提升整体利润率，更彰显了MiniMax在全球AI竞 争格局中的真实竞争力。"技术层面，MiniMax的M2.1大模型在编程能力与智 ...

Group 1 - The report assigns a "Outperform" rating to the company, with a target price of HKD 43.1 [1] Group 2 - The core viewpoint of the report indicates that the company is approaching a turning point, benefiting from the accelerated growth in optical radar installations and increased penetration in the high-level autonomous driving sector [1] - The report anticipates that the company's EM digital radar products will be the main driver of sales this year [1] - Additionally, the company is strengthening its positioning in the autonomous lawn mower and driverless van markets [1] - The report projects that the company will reach breakeven by the fourth quarter of 2025 [1]

Investment Rating - The investment rating for Minsheng Bank has been upgraded from "Neutral" to "Buy" by UBS [1] Core Insights - The upgrade is based on the bank's valuation being at a deep discount, with a projected price-to-book ratio of only 0.22 times for 2026, compared to 0.47 times for CITIC Bank [1] - UBS believes that the bank will benefit from revenue improvement and that the risks associated with its balance sheet have been largely mitigated, leading to a potential turning point in profitability starting in 2026 [1] - The target price for Minsheng Bank has been slightly adjusted down from HKD 5.43 to HKD 5.30 [1] - The market currently perceives ongoing profit pressure for Minsheng Bank, but UBS argues that the provisioning risks may have peaked [1] - Profitability is expected to stabilize in 2026 and turn to positive growth from 2027 onwards, indicating significant potential for valuation re-rating that could exceed recent weak equity returns [1] - UBS has raised its earnings per share forecast for Minsheng Bank for 2026 to 2029 by 5-6%, while slightly increasing the cost of equity (CoE) to 11.5% due to short-term market volatility [1]

Investment Rating - The report maintains a "Outperform" rating for Pop Mart (09992) with a target price of HKD 470 [1] Core Insights - Pop Mart is projected to achieve global sales of over 400 million units for its entire IP product line by 2025, with THEMONSTERS expected to contribute over 100 million units [1] - The report suggests that the increasing proportion of plush toys and overseas market sales will drive growth in average selling prices, leading to a forecasted revenue of RMB 38.4 billion, implying a year-on-year increase of 148% for Q4 2025 [1] - If the average selling price rises to RMB 100 per unit, total revenue could reach RMB 40 billion, with Q4 revenue estimated at RMB 13.6 billion, reflecting a year-on-year increase of 180% and a quarter-on-quarter increase of 9.2% [1] - The report highlights that the IP value contribution from THEMONSTERS may be higher due to a greater proportion of plush toys and MEGA series, which have higher average selling prices compared to trend toys [1] - The company is expected to manage its IP portfolio more cautiously by 2026 [1]

Investment Rating - The report assigns a "Buy" rating for the company, indicating a potential upside in the stock price [6][12]. Core Insights - The company has achieved global sales exceeding 400 million units, with the "THE MONSTERS" series alone accounting for over 100 million units sold [7]. - The company is expected to experience significant revenue growth in 2025, with projected revenues between RMB 35.6 billion and RMB 43.6 billion, representing a year-on-year increase of 173% to 234% [12]. - New product launches in late 2025 and early 2026 have generated positive market responses, with some products showing a premium of approximately 48% [12]. - The company is strengthening its long-term development foundation by expanding its membership base to over 100 million and increasing its global store count to over 700 [12]. - The company is exploring new business avenues, including jewelry, desserts, theme parks, clothing, and film [12]. - Profit forecasts for 2025 to 2027 are optimistic, with expected net profits of RMB 12.26 billion, RMB 17.8 billion, and RMB 24.6 billion, respectively, indicating substantial growth [12]. Financial Summary - The company reported a net profit of RMB 476 million in 2022, with projections of RMB 1.08 billion in 2023 and RMB 3.13 billion in 2024, reflecting a significant recovery and growth trajectory [10]. - Earnings per share (EPS) are expected to rise from RMB 0.35 in 2022 to RMB 9.13 in 2025, showcasing a strong growth rate [10]. - The price-to-earnings (P/E) ratio is projected to decrease from 685 in 2022 to 26 in 2025, indicating improved valuation as earnings grow [10].